Lunacell, a Korean company that specializes in single-cell analysis solutions, has successfully secured seed investment from the Osong Medical Innovation Foundation (KBIOHealth). Lunacell was selected for the TIPS R&D program in 2023 and is currently located in the Pangyo Startup Zone.

The single-cell analysis market is expanding rapidly each year, becoming a pivotal technology in life science and medical research. With the ability to conduct precise analyses at the single-cell level, groundbreaking research can be achieved in areas like personalized treatment development, disease diagnosis, and new drug discovery.

Lunacell is developing innovative single-cell analysis solutions to keep pace with market growth and technological advancements. This seed investment provides a strong financial foundation for Lunacell to focus on technology development. The collaboration with the KBIOHealth, an organization affiliated with the Ministry of Health and Welfare of Korea and based in Cheongju, North Chungcheong Province, enables Lunacell to leverage additional resources.

Kim Jae-hoon, CEO of Lunacell, expressed his enthusiasm about the investment from a leader in Korea’s bio industry. “This investment not only solidifies our foundation but also strengthens our partnership with the foundation, allowing us to fully utilize their human and material resources,” he said. He also shared his vision for the future, stating, “Lunacell aims to become the leading single-cell analysis solution provider in Korea.”